1-15 of 177
What the Latest IgAN Clinical Trials Mean for Patient Care
On the Frontlines of IgA NephropathyWhat the Latest IgAN Clinical Trials Mean for Patient Care
Steve Jackson, PharmD
Andrew S. Bomback, MD, MPH
Gates B. Colbert, MD
Anjay Rastogi, MD, PhD
Targeting BAFF and APRIL in IgA Nephropathy
On the Frontlines of IgA NephropathyTargeting BAFF and APRIL in IgA Nephropathy
Gates B. Colbert, MD
Edgar V. Lerma, MD, FACP, FASN, FPSN (Hon)
Early Combination Therapy in IgA Nephropathy
On the Frontlines of IgA NephropathyEarly Combination Therapy in IgA Nephropathy
Gates B. Colbert, MD
Sayna Norouzi, MD
Reading the Warning Signs: Risk Stratification in IgAN
On the Frontlines of IgA NephropathyReading the Warning Signs: Risk Stratification in IgAN
Gates B. Colbert, MD
Dustin Le, MD, MHS
Not Just for Diabetes: Broadening uACR Screening to CV Risk Populations
Conversations in CV Risk AssessmentNot Just for Diabetes: Broadening uACR Screening to CV Risk Populations
Brian P. McDonough, MD, FAAFP
Anu Lala, MD
- advertisement
Unseen Disease: The Diagnostic Barriers to CKD and CV Risk Prevention
Conversations in CV Risk AssessmentUnseen Disease: The Diagnostic Barriers to CKD and CV Risk Prevention
Jennifer Caudle, DO, FACOFP
Dustin Le, MD, MHS
Niloo Nobakht, MD, FASN
Hypertension in Women: Cardiovascular Risk Across the Lifespan
Heart MattersHypertension in Women: Cardiovascular Risk Across the Lifespan
Shelina Ramnarine, PhD
Payal Kohli, MD, FACC
Predicting the Heart’s Future: Albuminuria as a CV Warning Sign
Conversations in CV Risk AssessmentPredicting the Heart’s Future: Albuminuria as a CV Warning Sign
Brian P. McDonough, MD, FAAFP
Anu Lala, MD
Heart Failure and Albuminuria: Connecting the Dots
Conversations in CV Risk AssessmentHeart Failure and Albuminuria: Connecting the Dots
Jennifer Caudle, DO, FACOFP
Robert J. Mentz, MD, FHFSA, FACC
Bridging the Gap: From Screening to Cardiovascular Risk Diagnosis
Conversations in CV Risk AssessmentBridging the Gap: From Screening to Cardiovascular Risk Diagnosis
Jennifer Caudle, DO, FACOFP
Dustin Le, MD, MHS
Niloo Nobakht, MD, FASN
The Risk Equation: Combining uACR and eGFR for CV Prediction
Conversations in CV Risk AssessmentThe Risk Equation: Combining uACR and eGFR for CV Prediction
Matthew Sorrentino, MD
Ashish Verma, MBBS
- advertisement
Albuminuria: An Overlooked Red Flag in Cardiovascular Risk
Conversations in CV Risk AssessmentAlbuminuria: An Overlooked Red Flag in Cardiovascular Risk
Matthew Sorrentino, MD
Ashish Verma, MBBS
Hidden High Risk: When BP Control Isn’t Enough in Hypertension
Conversations in CV Risk AssessmentHidden High Risk: When BP Control Isn’t Enough in Hypertension
Gates B. Colbert, MD
Michael E. Hall, MD
Clyde W. Yancy, MD
Understanding Residual Cardiovascular Risk in CKD and T2D
Diabetes DiscourseUnderstanding Residual Cardiovascular Risk in CKD and T2D
John W. Ostrominski, MD, MPH
